Material Event (Form 8-K)

Item 8.01 Other Events.

On February 6, 2026, Enveric Biosciences, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") to register an additional $1,346,000 of shares (the "Shares") of its common stock, par value $0.01 per share ("Common Stock"), issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC (the "Sales Agent"), dated April 9, 2025 (the "ATM Agreement"). Prior to the date hereof, the Company has sold an aggregate of $1,853,878.34 shares of its Common Stock through the Sales Agent under the ATM Agreement. An opinion regarding the legality of the Shares issuable under the ATM Agreement and covered by the Prospectus Supplement is filed as Exhibit 5.1 to this Current Report on Form 8-K.